The healthcare guidance body, NICE, has issued new draft guidance that does not recommend lenalidomide (Revlimid, Celgene), for treating myelodysplastic syndromes (MDS). The FDA approved the treatment ...

Revlimid (lenalidomide) is a brand-name oral capsule that’s prescribed for certain types of myeloma, lymphoma, and anemia. As with other drugs, Revlimid can cause side effects, such as skin rash and ...

Doctors prescribe Revlimid (lenalidomide) to treat certain blood cancers, including multiple myeloma, mantle cell lymphoma, and others. The drug is not safe to take while pregnant, and doctors avoid ...

On a busy morning after Bristol Myers Squibb revealed that the FDA approved its potential blockbuster Camzyos, the pharma giant also introduced negative news about a fading blockbuster. Sales of ...

An eye-opening social media reel has gone viral, showcasing the drastic variation in cancer medication prices between India ...

BOSTON, June 6 (Reuters) - Two major studies of Celgene Corp's multiple myeloma drug Revlimid showed that when taken as maintenance therapy following stem-cell transplantation it reduced the risk of ...

The combination of Revlimid with dexamethasone, previously approved for treatment in patients with multiple myeloma who received at least 1 prior treatment, has received FDA approval for use in newly ...

Maintenance Revlimid was shown to improve overall survival in patients with multiple myeloma. Patients with multiple myeloma saw a 26 percent decrease in risk of death when they took maintenance ...

BOSTON, Dec 7 (Reuters) - Celgene Corp said on Monday that a trial of its cancer drug Revlimid showed it reduced the risk of disease progression in newly diagnosed patients with multiple myeloma by 50 ...

On May 7, 2015, the European Patent Office (EPO) revoked one of Celgene's ( CELG) patents on Revlimid®. Revlimid® reportedly accounts for almost $5 billion of Celgene's nearly $7.5 billion in annual ...

When Bristol Myers Squibb agreed to buy Celgene for $74 billion last year, analysts wondered if it was worth the price—and they specifically called out patent challenges to Celgene's top-selling ...